Fintel reports that Renaissance Technologies has filed a 13G/A form with the SEC disclosing ownership of 2.81MM shares of Enzo Biochem, Inc. (ENZ). This represents 5.78% of the company.
In their previous filing dated February 14, 2022 they reported 3.09MM shares and 6.38% of the company, a decrease in shares of 9.07% and a decrease in total ownership of 0.60% (calculated as current - previous percent ownership).
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Enzo Biochem. This is a decrease of 6 owner(s) or 6.06% in the last quarter. Average portfolio weight of all funds dedicated to ENZ is 0.31%, an increase of 10.24%. Total shares owned by institutions decreased in the last three months by 3.74% to 23,668K shares. The put/call ratio of ENZ is 0.35, indicating a bullish outlook.
What are large shareholders doing?
Harbert Fund Advisors holds 5,176K shares representing 10.62% ownership of the company. No change in the last quarter.
Roumell Asset Management holds 2,390K shares representing 4.91% ownership of the company. No change in the last quarter.
RAMSX - Roumell Opportunistic Value Fund Institutional Class holds 2,239K shares representing 4.59% ownership of the company. In it's prior filing, the firm reported owning 2,390K shares, representing a decrease of 6.77%. The firm decreased its portfolio allocation in ENZ by 14.29% over the last quarter.
VIEX Capital Advisors holds 1,334K shares representing 2.74% ownership of the company. In it's prior filing, the firm reported owning 1,537K shares, representing a decrease of 15.17%. The firm increased its portfolio allocation in ENZ by 14.45% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,041K shares representing 2.14% ownership of the company. No change in the last quarter.
Enzo Biochem Background Information
(This description is provided by the company.)
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
